Ripple Therapeutics is a clinical stage ophthalmic therapeutics company that specializes in sustained drug delivery through its innovative prodrug technology, which eliminates the need for polymers. Their flagship product, Epidel™, allows for precise control of drug dosing and duration, improving patient outcomes and reducing treatment burdens. The company has demonstrated significant traction with successful clinical trials and strategic partnerships, including a collaboration with Abb Vie to develop a biodegradable implant for glaucoma management. Ripple's technology positions it uniquely in the ophthalmic market, addressing critical needs in drug delivery for conditions like glaucoma and retinal diseases.
Something looks off?